Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Titel:
Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Auteur:
Chehrehgosha, Haleh Sohrabi, Masoud Reza Ismail-Beigi, Faramarz Malek, Mojtaba Reza Babaei, Mohammad Zamani, Farhad Ajdarkosh, Hossein Khoonsari, Mahmood Fallah, Afshin Eshghi Khamseh, Mohammad E.